Erlizumab

Source: Wikipedia, the free encyclopedia.
Erlizumab
CD18
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Erlizumab, also known as rhuMAb, is a

traumatic shock.[1]

Mechanism of action

The drug works by blocking a growth factor in blood vessels.

LFA-1 integrin.[3] Erlizumab was meant to stop lymphocyte movement into inflamed tissue, thereby reducing tissue damage.[4]

Clinical trials

Genentech started clinical trials on the drug in October 1996.[5] During clinical trials, six patients suddenly started coughing up blood, and four of them later died.[2] In June 2000, preliminary phase II clinical trial results showed that erlizumab did not meet Genentech's goals.[1] Genentech's primary goal was for the drug to increase blood flow to the heart within 90 minutes of administering the medicine.[4]

Other anti-CD18 drugs

Multiple companies have tried to develop anti-CD18 drugs, but none of them have been successful.

Centocor.[4] Although trials in humans have not gone well, the research of CD18 drugs in animals has been encouraging.[4] It is thought that the experimental medicines are affecting the lymphocyte adhesion pathway in humans in unintended ways.[4] One hypothesis is that the endothelial cell barrier function fails when blood supply is low for a prolonged time in humans.[6] If this is true, the drug is not able to stop lymphocyte movement into inflamed tissue.[6]

References

  1. ^ a b "Genentech Announces Phase II Trial of Experimental Anti-CD18 Antibody Did Not Meet Its Primary Objectives". Business Wire. June 16, 2000. Retrieved January 29, 2009.
  2. ^ a b Altman L (May 30, 2000). "THE DOCTOR'S WORLD; In Search of Surprises as Cures for Cancer". The New York Times. Retrieved January 29, 2009.
  3. PMID 17084981
    .
  4. ^
    S2CID 190257
    .
  5. ^ "Genentech Reports 1996 Third Quarter Results". Genentech. October 21, 1996. Retrieved January 31, 2009.
  6. ^
    PMID 11733394
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Erlizumab&oldid=1170982758"